Patents by Inventor Stanford L. PENG

Stanford L. PENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
    Patent number: 12202882
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: January 21, 2025
    Assignee: ALPINE IMMUNE SCIENCES, INC.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20250019412
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 16, 2025
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20250019413
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: September 24, 2024
    Publication date: January 16, 2025
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20240400643
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: August 16, 2024
    Publication date: December 5, 2024
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • METHODS OF DOSING AND TREATMENT WITH A TACI-FC FUSION IMMUNOMODULATORY PROTEIN
    Publication number: 20240279310
    Abstract: Provided herein are methods of treatment and uses involving an immunomodulatory TACI-Fc fusion protein that exhibits neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The provided TACI-Fc protein may include variant domains of Transmembrane Activator and CAML Interactor (TACI). The methods and uses provide therapeutic utility for a variety of immunological diseases, disorders or conditions, such as B cell-mediated diseases, disorder or conditions.
    Type: Application
    Filed: May 6, 2022
    Publication date: August 22, 2024
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Jing YANG, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20240218045
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 4, 2024
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS WITH AND WITHOUT A T CELL INHIBITORY PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230241168
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers) alone, or also coupled with inhibition of T cell costimulation. The immunomodulatory proteins provided herein include variant domains of B cell maturation antigen (BCMA) alone, or multi-domain immunomodulatory protein that inhibit B cell responses and also can inhibit T cell costimulation. Also provided are nucleic acids molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 3, 2023
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG, Ryan SWANSON
  • METHODS AND USES OF VARIANT CD80 FUSION PROTEINS AND RELATED CONSTRUCTS
    Publication number: 20220177587
    Abstract: Provided herein are variant CD80 polypeptides, immunomodulatory proteins comprising variant CD80 polypeptides, and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of oncological conditions. Compositions and methods for making and using such proteins are provided.
    Type: Application
    Filed: September 19, 2019
    Publication date: June 9, 2022
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Ryan SWANSON, Mark F. MAURER, Stanford L. PENG, Jing YANG, Kristine M. SWIDEREK
  • APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
    Patent number: 11274140
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 15, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20210388054
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 16, 2021
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG
  • APRIL AND BAFF INHIBITORY IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20210363223
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Application
    Filed: June 11, 2021
    Publication date: November 25, 2021
    Applicant: Alpine Immune Sciences, Inc.
    Inventors: Stacey DILLON, Mark RIXON, Lawrence EVANS, Daniel William DEMONTE, Joseph L. KUIJPER, Stanford L. PENG